UBS and Truist Securities maintain cautious ratings on IBM, reflecting uncertainty about when increased corporate spending on AI infrastructure will boost demand for IBM's products and services. While IBM's offerings like Red Hat software and watsonx Orchestrate show strong potential, analysts question the timing of customer demand and the company's execution capabilities. IBM's stock is currently trading around $232, with a market value of about $218 billion. The cautious outlook highlights the challenges in predicting near-term growth despite IBM's innovative AI-related solutions.
IBM stock outlook offers context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Oct 13, 2026 22:41 WIB: Among 150 priced US tech stocks, 66 rose and 83 fell. Notable movers include Wipro Limited (WIT) at USD 1.79 with a 1-day change of +5.59%, Arista Networks Inc (ANET) at USD 199.21 down 5.53%, and Teradyne, Inc. (TER) at USD 363.82 down 5.22%. Typical hold times range from 37 to 53 days, with buy activity dominating for these movers.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
